13,179 Shares in Altimmune, Inc. (NASDAQ:ALT) Acquired by WealthPlan Investment Management LLC

WealthPlan Investment Management LLC acquired a new position in Altimmune, Inc. (NASDAQ:ALT – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,179 shares of the company’s stock, valued at approximately $135,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Bank of New York Mellon Corp grew its position in Altimmune by 49.0% during the third quarter. Bank of New York Mellon Corp now owns 73,096 shares of the company’s stock valued at $934,000 after acquiring an additional 24,051 shares during the last quarter. Telemetry Investments L.L.C. grew its position in Altimmune by 11.5% during the third quarter. Telemetry Investments L.L.C. now owns 14,500 shares of the company’s stock valued at $185,000 after acquiring an additional 1,500 shares during the last quarter. Advisory Research Inc. bought a new position in Altimmune during the third quarter valued at approximately $448,000. Balyasny Asset Management LLC grew its position in Altimmune by 402.6% during the third quarter. Balyasny Asset Management LLC now owns 1,037,662 shares of the company’s stock valued at $13,251,000 after acquiring an additional 831,193 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC grew its position in Altimmune by 7,091.2% during the third quarter. BNP Paribas Arbitrage SNC now owns 82,339 shares of the company’s stock valued at $1,051,000 after acquiring an additional 81,194 shares during the last quarter. 93.69% of the stock is currently owned by institutional investors.

Altimmune Stock Up 0.5 %

Shares of ALT stock opened at $11.01 on Friday. The stock has a fifty day moving average of $13.10 and a 200 day moving average of $12.89. Altimmune, Inc. has a 52 week low of $3.83 and a 52 week high of $23.49. The firm has a market capitalization of $542.57 million, a price-to-earnings ratio of -6.22 and a beta of 0.11.

Altimmune (NASDAQ:ALT – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.09. Altimmune had a negative return on equity of 44.02% and a negative net margin of 2,618.74%. The company had revenue of ($0.11) million during the quarter, compared to analyst estimates of $0.11 million. Equities research analysts anticipate that Altimmune, Inc. will post -1.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Evercore ISI increased their price objective on Altimmune from $14.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, January 18th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Altimmune in a research note on Thursday, March 9th. Finally, The Goldman Sachs Group assumed coverage on Altimmune in a research note on Thursday, December 1st. They set a “buy” rating and a $20.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $29.13.

Insider Buying and Selling

In other Altimmune news, Director Wayne Pisano sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 22nd. The stock was sold at an average price of $15.01, for a total transaction of $300,200.00. Following the completion of the transaction, the director now owns 8,498 shares of the company’s stock, valued at $127,554.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 3.19% of the stock is currently owned by insiders.

Altimmune Profile

(Get Rating)

Altimmune, Inc is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.